Dr
Markus
Zoller

Partner & Patent Attorney

Munich Office Heidelberg Office

Life sciences

Telephone. +49(0) 891 259 9600
Mobile. +49(0) 172 852 0370
Email. [email protected]

Experience

The kind of clients Markus works with ranges from single inventors to large-scale enterprises. Besides drafting of patent applications and prosecution, Markus offers guidance to his clients in terms of patent portfolio management and litigation strategies.

Markus advises his clients in the fields of trade mark and design law.

Before starting in a large Munich patent law firm he worked in a patent law firm in New York City.

Markus holds a Bachelor and Master’s degree of Science in molecular Biotechnology at the Technical University in Munich. During his studies Markus worked at the University of Amsterdam and studied one semester at the Nanyang Technological University in Singapore. After three years of research at the Max-Planck Institute for Infectious Biology in Berlin he received his Doctor’s degree in the field of molecular biology, especially (auto) antibodies.

Markus is a Patentanwalt (German Patent Attorney), European Patent Attorney as well as European Trade Mark and Design Attorney.

Qualifications

Patent Attorney

Austrian
European
German

Patentanwalt

Trade Mark Attorney

Austrian
European
German


BSC

BSc in Science

MSC

MSc in Science

PHD

PHD in Immunobiology

Conferences: 2020

January 29th 2020

AIPLA

Attended

Conferences: 2018

October 18th 2018

APAA

Attended

CSR

Markus is providing training sessions to German Patent and Trade Mark Attorney and European Patent Attorney Trainees and also to support staff.

Further, he is a member of the examination board for German patent paralegals (Patentanwaltsfachangestellte).

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

3D shape trade marks for medical devices

Innovation in medical devices continues strongly and the introduction of IoT and 3D printing (amongst others) has led to an acceleration in new medical devices. Whilst patents and designs are …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

“For medical purposes” – a case for unblurring the lines between pharma and nutritional products

Food-pharma industry convergence is not a new development. In 2013, a study of the patent citation data of 274 published European patents by 5 EU Medical Nutrition companies revealed the …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article
Event - 30th April 2022

INTA 2022 Annual Meeting Live+

The HGF European team will be attending the INTA 2022 Annual Meeting Live+. It is being held on 30th April – 4th May in Washington, D.C. INTA brings together the …

Event details

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.